Many Skin Cancer Patients Do Not Receive Sentinel Lymph Node Biopsy Although clinical practice guidelines recommend sentinel lymph node (SLN) biopsy for many patients with clinically node-negative melanoma, a new analysis from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) has found approximately half of patients do not receive reco
Source: www.medicalnewstoday.comESRI's ArcPad 8 Features Improved Customization and User Interface Edits to Geodatabase Can Now be Synced via ArcGIS Server (PRWeb Apr 10, 2009)
Read the full story at http://www.prweb.com/releases/ArcPad8/ESRI/prweb2312054.htm
Source: www.prweb.comNeudesic to Deliver Webinar Focusing on Marketing Automation Platform Neudesic today announced a Marketing Automation webinar highlighting its strategic alliance with Microsoft and ExactTarget, and the Actionable Marketing Intelligence Solution the companies are combining to offer. The webinar presentation will take place on April 28th and is positioned to illuminate the value of an integrated end-to-end Marketing Automation Platform (MAP) solution. (PRWeb Apr 10, 2009)
Read the full story at http://www.prweb.com/releases/2009/04/prweb2315474.htm
Source: www.prweb.comRenowned Smoking Cessation Expert Launches Popular Stop Smoking Seminar across U.S. and UK America's favorite Smoking Cessation Expert Franc Tausch is launching his popular Stop Smoking Seminar in major metropolitan areas across the U.S. and in London, UK. Attendees quit smoking in one day, without nicotine withdrawal or weight gain. (PRWeb Apr 9, 2009)
Read the full story at http://www.prweb.com/releases/stop_smoking/quit_smoking/prweb2308944.htm
Source: www.prweb.comMedivation Announces Publication In Science Describing MDV3100's Novel And Potent Anti-Androgen Properties Medivation, Inc. (Nasdaq: MDVN) announced publication of an article in the April 9, 2009, issue of Science Express, the online version of the journal Science, presenting the discovery and novel mechanism of action of MDV3100, the Company's androgen receptor antagonist drug candidate. MDV3100 has completed enrollment in a Phase 1-2 study and is expected to enter Phase 3 development this year in metastatic castration-resistant prostate cancer (CRPC).
Source: www.medicalnewstoday.comPsoriatic Arthritis: New Drug Shows Promising Results Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor α (anti-TNFα) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNFα and has been shown to be beneficial within two weeks of the first subcutaneous injection in a phase II rheumatoid arthritis trial.
Source: www.medicalnewstoday.com
# posted by Network @ 1:22 PM
